NPS Pharmaceuticals Price Target Increased to $39.00 by Analysts at Summer Street (NPSP)
Investment analysts at Summer Street increased their price objective on shares of NPS Pharmaceuticals (NASDAQ:NPSP) from $33.00 to $39.00 in a note issued to investors on Wednesday, AnalystRatings.Net reports. The firm currently has a “buy” rating on the stock. Summer Street’s price target would suggest a potential upside of 24.96% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at Merrill Lynch initiated coverage on shares of NPS Pharmaceuticals in a research note to investors on Thursday, October 3rd. They set a “buy” rating and a $46.00 price target on the stock. Separately, analysts at Wedbush set a $43.00 price target on shares of NPS Pharmaceuticals in a research note to investors on Thursday, October 3rd. They now have an “outperform” rating on the stock. Finally, analysts at Bank of America Corp. initiated coverage on shares of NPS Pharmaceuticals in a research note to investors on Thursday, October 3rd. They set a “buy” rating and a $46.00 price target on the stock. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $34.24.
NPS Pharmaceuticals (NASDAQ:NPSP) opened at 31.21 on Wednesday. NPS Pharmaceuticals has a 52-week low of $7.35 and a 52-week high of $35.72. The stock’s 50-day moving average is $28.75 and its 200-day moving average is $18.75. The company’s market cap is $3.166 billion.
NPS Pharmaceuticals (NASDAQ:NPSP) last released its earnings data on Thursday, August 8th. The company reported ($0.13) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.07) by $0.06. The company had revenue of $36.50 million for the quarter, compared to the consensus estimate of $31.62 million. During the same quarter in the prior year, the company posted $0.08 earnings per share. The company’s quarterly revenue was down 31.8% on a year-over-year basis. On average, analysts predict that NPS Pharmaceuticals will post $-0.21 earnings per share for the current fiscal year.
NPS Pharmaceuticals, Inc (NASDAQ:NPSP) is a clinical-stage biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.